PSS World Medical
The 10-second takeaway
For the quarter ended March 30 (Q4), PSS World Medical missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share stayed the same.
Gross margins improved, operating margins dropped, net margins dropped.
PSS World Medical chalked up revenue of $538.9 million. The nine analysts polled by S&P Capital IQ predicted sales of $556.0 million on the same basis. GAAP reported sales were 2.0% lower than the prior-year quarter's $549.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.38. The eight earnings estimates compiled by S&P Capital IQ predicted $0.43 per share. GAAP EPS of $0.38 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 32.6%, 110 basis points better than the prior-year quarter. Operating margin was 6.6%, 30 basis points worse than the prior-year quarter. Net margin was 3.7%, 20 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $510.8 million. On the bottom line, the average EPS estimate is $0.29.
Next year's average estimate for revenue is $1.99 billion. The average EPS estimate is $1.44.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 60 members out of 63 rating the stock outperform, and four members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 25 give PSS World Medical a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PSS World Medical is hold, with an average price target of $25.38.
If you're interested in health care stocks like PSS World Medical, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
- Add PSS World Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.